# US 10,370,336 B2 · Phenyl-cyanoquinolinone PDE9 inhibitors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 10,370,336 B2
- Document ID: US10370336B2
- Status: Granted
- Kind: B2
- Application number: 15/745,845
- Filed: 2016-07-27
- Published: 2018-07-26
- Granted: 2019-08-06
- Earliest claimed: 2015-07-29
- Assignees: Merck Sharp & Dohme Corp.
- Applicants: Merck Sharp & Dohme Corp.
- Inventors: Victoria Cofre; Antonella Converso; Kevin Rodzinak
- Web page: https://patentgrep.com/patent/US10370336B2

## CPC

- C07D 215/54: attached in position 3
- A61P 25/14: for treating abnormal movements, e.g. chorea, dyskinesia
- A61P 25/18: Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention is directed to phenylcyanoquinolinone compounds which may be useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 9 (PDE9). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.

## Claims

### Claim 1

A compound of the formula Ia, or a pharmaceutically acceptable salt thereof:
wherein:
R6 is methyl or ethyl;
R5 is hydrogen; and
R7 is hydrogen or fluoro.

### Claim 2 (depends on 1)

The compound of claim 1 wherein R5 is hydrogen, R7 is hydrogen and R6 is methyl or ethyl.

### Claim 3

A compound which is selected from the group consisting of:
or a pharmaceutically acceptable salt thereof.

### Claim 4 (depends on 1)

A pharmaceutical composition which comprises an inert carrier and a compound of claim 1 or a pharmaceutically acceptable salt thereof.

### Claim 5 (depends on 1)

A method for treating a neurological or psychiatric disorder associated with PDE9 dysfunction in a mammalian patient in need thereof which comprises administering to the patient a therapeutically effective amount of a compound of claim 1 or a pharmaceutically acceptable salt thereof.

### Claim 6 (depends on 1)

A method for treating bipolar disorder, anxiety, schizophrenia, neurological or psychiatric disorder associated with PDE9 dysfunction and further associated with striatal hypofunction or basal ganglia dysfunction in a mammalian patient in need thereof which comprises administering to the patient a therapeutically effective amount of a compound of claim 1 or a pharmaceutically acceptable salt thereof.

### Claim 7 (depends on 1)

A method for treating Huntington's disease associated with PDE9 dysfunction in a mammalian patient in need thereof which comprises administering to the patient a therapeutically effective amount of a compound of claim 1 or a pharmaceutically acceptable salt thereof.

### Claim 8 (depends on 1)

A method for enhancing cognition associated with PDE9 dysfunction in a mammalian patient in need thereof which comprises administering to the patient a therapeutically effective amount of a compound of claim 1 or a pharmaceutically acceptable salt thereof.